...
首页> 外文期刊>TMR Cancer >Anti-cancer drugs targeting using nanocarrier niosomes-a review
【24h】

Anti-cancer drugs targeting using nanocarrier niosomes-a review

机译:使用NanoCarrier Niosomes靶向抗癌药物 - 评论

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In the last few decades numbers of review and research articles have been published on niosomes. This shows the relevant interest of academias & researchers in niosomes because of the advantages sponsored by them over other colloidal drug delivery systems. Niosomes formation occurs when non-ionic surfactant vesicles assemble themselves. Various antineoplastic agents are used in chemotherapy, but they have some drawbacks that these agents cause cell death in normal tissues as well. There are two approaches to overcome this limitation. First, to modify the structure of existing drugs, but this will not possible because it changes the properties of drugs. Second, the development of nano-carriers like liposomes, dendrimers, nanoparticles, niosomes et al. Among all, niosomes (non-ionic surfactant vesicles) have more advantages besides all nano-carriers. Drugs either hydrophilic in nature or hydrophobic in nature, both can be incorporated in niosomes. And by embedding specific ligands over vesicular surface enables us to target the drug to specific cancer cells.
机译:在过去的几十年里,已在尼罗斯公布的审查和研究文章中。这表明学术界和研究人员在尼罗斯的相关兴趣,因为它们由其他胶体药物递送系统赞助。当非离子表面活性剂囊泡组装自身时,发生定位组织形成。各种抗肿瘤剂用于化疗,但它们具有一些缺点,即这些药剂也导致正常组织中的细胞死亡。有两种方法可以克服这种限制。首先,修改现有药物的结构,但这是不可能的,因为它会改变药物的性质。其次,纳米载体的发展如脂质体,树枝状大分子,纳米粒子,Niosomes等。其中,除了所有纳米载体之外,Niosomes(非离子表面活性剂囊泡)具有更多的优点。药物本质上亲水或本质上的疏水性,两者都可以掺入Niosomes中。通过将特异性配体嵌入囊状表面,使我们能够将药物靶向特异性癌细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号